협심증 치료제 시장 : 시장 예측(2026-2032년)

The Angina Pectoris Drugs Market is projected to grow by USD 19.59 billion at a CAGR of 6.47% by 2032.

Angina pectoris drugs remain central to the clinical management of coronary artery disease, stable angina, vasospastic angina, microvascular angina, and acute coronary syndrome-related ischemic symptoms. The therapeutic landscape includes nitrates, beta blockers, calcium channel blockers, antiplatelet agents, anticoagulants, lipid-lowering therapies, ranolazine, and other anti-ischemic medicines used to reduce myocardial oxygen demand, improve coronary blood flow, prevent thrombotic complications, and lower recurrent cardiovascular risk. Demand is supported by the persistent global burden of ischemic heart disease, which the World Health Organization identifies as the leading cause of death worldwide, and by aging populations, hypertension, diabetes, obesity, smoking exposure, and sedentary lifestyles that increase coronary artery disease risk. Clinical guidelines continue to emphasize individualized pharmacotherapy, combining symptom relief with secondary prevention through blood pressure control, lipid management, antithrombotic therapy, lifestyle modification, and timely revascularization when indicated. Within this environment, stakeholders are focusing on evidence-based prescribing, improved adherence, safer long-term treatment pathways, and integrated care models that connect primary care, cardiology, emergency medicine, diagnostics, and pharmacy services.

Transformative Shifts Reshaping the Angina Pectoris Drug Landscape

The angina pectoris drugs landscape is undergoing a structural shift from symptom-focused treatment toward comprehensive ischemic heart disease management. Contemporary care increasingly differentiates stable chronic coronary syndrome, microvascular angina, vasospastic angina, and acute coronary presentations, enabling more targeted use of beta blockers, calcium channel blockers, long-acting nitrates, antiplatelet therapies, anticoagulants, and metabolic antianginal agents. Another major shift is the growing emphasis on long-term risk reduction, as lipid-lowering intensification, blood pressure optimization, diabetes management, and smoking cessation are now closely linked with antianginal therapy decisions. Generic availability has expanded access to many first-line drugs, while innovation is concentrated on improved formulations, combination regimens, safer antithrombotic strategies, real-world evidence generation, and digital adherence support. Health systems are also moving care closer to patients through outpatient chest pain pathways, telecardiology, home blood pressure monitoring, electronic prescribing, and pharmacist-led medication reviews. At the same time, stricter pharmacovigilance expectations, polypharmacy stewardship, and payer scrutiny of clinical value are reshaping how angina drugs are selected, reimbursed, and monitored across settings.

Cumulative Impact of Artificial Intelligence on Angina Pectoris Drug Development and Care

Artificial intelligence is increasingly influencing the angina pectoris drugs ecosystem across discovery, diagnosis, prescribing, adherence, and safety surveillance. In research and development, machine learning supports target identification, molecular screening, trial feasibility assessment, and patient stratification for cardiovascular drug studies, helping investigators detect phenotypes such as microvascular dysfunction, vasospasm, high thrombotic risk, or medication intolerance. In clinical practice, AI-enabled interpretation of electrocardiograms, imaging, laboratory patterns, and electronic health records can support earlier recognition of ischemic risk and guide evidence-aligned treatment escalation. Predictive analytics can identify patients at higher risk of recurrent angina, hospital readmission, bleeding complications, hypotension, bradycardia, or poor adherence, enabling proactive medication adjustment and closer follow-up. AI also strengthens pharmacovigilance by detecting adverse event signals from real-world datasets and supporting safer use of antiplatelet, anticoagulant, nitrate, beta blocker, and calcium channel blocker therapies. However, the cumulative impact depends on transparent validation, clinically representative datasets, cybersecurity, interoperability, explainability, and governance that prevents algorithmic bias in cardiovascular care.

Key Regional Insights Across Asia-Pacific, Europe, North America, Latin America, Africa, and Middle East

Asia-Pacific is shaped by a high and rising cardiovascular disease burden, rapid urbanization, expanding health insurance coverage, and wide variation in access between advanced health systems and resource-constrained settings. China, India, Japan, South Korea, and Australia demonstrate strong use of guideline-based pharmacotherapy, while affordability, early diagnosis, and adherence remain key priorities in several emerging markets. Europe maintains a highly guideline-driven environment supported by established cardiovascular prevention programs, pharmacovigilance systems, reimbursement frameworks, and clinical practice alignment for chronic coronary syndromes, while managing polypharmacy in aging populations. North America benefits from mature cardiology infrastructure, broad availability of antianginal and secondary prevention medicines, strong emergency care pathways, and extensive use of electronic health records, although medication affordability and disparities in preventive cardiovascular care remain important policy concerns. Latin America is characterized by expanding access to essential cardiovascular medicines, a growing focus on hypertension, diabetes, and dyslipidemia control, and persistent gaps in specialist availability across rural and underserved areas. Africa presents a dual challenge of rising noncommunicable disease burden and uneven access to diagnostics, trained professionals, and continuous medicine supply, making essential drug availability, primary care strengthening, and affordable generics central to angina management. The Middle East shows increasing demand linked to diabetes, obesity, smoking, and metabolic syndrome prevalence, with Gulf health systems investing in specialized cardiac services, preventive screening, and digital health infrastructure.

Key Group Insights Across NATO, G7, BRICS, European Union, ASEAN, and GCC

NATO member countries overlap significantly with high-income cardiovascular care systems in North America and Europe, where resilient medicine supply chains, emergency preparedness, and standardized care pathways are increasingly relevant for ensuring continuity of angina and coronary artery disease treatment during public health or geopolitical disruptions. G7 countries generally demonstrate mature reimbursement systems, established clinical pathways, strong secondary prevention practices, and advanced pharmacovigilance, making them important reference points for real-world evidence, patient safety monitoring, and guideline implementation. BRICS economies represent diverse but influential cardiovascular environments, combining large patient populations, expanding domestic pharmaceutical capacity, and increasing investment in digital health, while still facing disparities in access, adherence, and specialist care. The European Union supports angina pectoris drug adoption through harmonized medicine regulation, active pharmacovigilance, health technology assessment, and clinical guideline alignment, with a growing focus on medication safety in older adults and cross-border evidence generation. ASEAN countries are expanding cardiovascular care through universal health coverage initiatives, essential medicine lists, and regional efforts to improve noncommunicable disease prevention, but uneven diagnostic capacity and out-of-pocket expenditure continue to affect timely angina treatment. GCC health systems are prioritizing cardiometabolic disease management due to high rates of diabetes, obesity, and hypertension, creating strong emphasis on integrated cardiology services, preventive screening, and access to advanced therapeutics.

Key Country Insights for China, United States, Japan, India, Germany, and Major Care Systems

China is expanding cardiovascular services through hospital modernization, insurance reforms, domestic medicine production, and strengthened chronic disease management, while access variation between urban tertiary centers and lower-tier settings continues to shape angina drug utilization. The United States has a highly developed angina care environment supported by advanced diagnostics, emergency cardiac networks, broad drug availability, and strong guideline-based secondary prevention, though adherence and affordability remain important challenges. Japan's aging population and high clinical standards support careful antianginal therapy selection, particularly where bradycardia, hypotension, renal function, and polypharmacy require close monitoring. India's priorities include affordability, generic access, early diagnosis, and management of diabetes, hypertension, and dyslipidemia across a large and diverse patient base. Germany, the United Kingdom, France, Italy, and Spain operate within mature European care models where clinical guidelines, reimbursement structures, pharmacovigilance, and aging population needs shape angina drug utilization, with increasing emphasis on medication review and integrated chronic coronary syndrome management. Australia benefits from strong primary care, reimbursement mechanisms, preventive cardiology frameworks, and established pathways for risk-factor control, while South Korea combines advanced hospital infrastructure, digital health adoption, and high diagnostic capacity to support evidence-based angina treatment. Canada emphasizes publicly supported access, chronic disease management, and cardiovascular prevention across provinces, with ongoing attention to rural access and wait times. Russia continues to address cardiovascular mortality through broader prevention, improved hypertension control, and access to essential cardiac medicines across geographically dispersed populations. Brazil and Mexico face substantial burdens from hypertension, diabetes, obesity, and smoking exposure, driving the need for affordable generics, stronger primary care pathways, and consistent access to antiplatelet, beta blocker, nitrate, calcium channel blocker, and lipid-lowering therapies.

Actionable Recommendations for Leaders in Angina Pectoris Drug Strategy

Industry leaders should prioritize evidence-based differentiation by aligning angina pectoris drug strategies with contemporary cardiovascular guidelines, real-world patient needs, and measurable outcomes such as symptom control, adherence, bleeding avoidance, blood pressure stability, and reduced recurrent ischemic risk. Portfolio planning should address both acute and chronic care pathways, including stable angina, vasospastic angina, microvascular angina, and post-acute coronary syndrome management. Organizations should invest in real-world evidence, pharmacovigilance analytics, patient-reported outcomes, and adherence programs that support safer long-term medication use. Access strategies should reflect regional affordability realities by strengthening generic availability, reliable supply chains, essential medicine alignment, and partnerships with hospitals, payers, pharmacies, and primary care networks. Digital tools should be deployed to support medication reminders, remote monitoring, clinical decision support, and risk stratification, but must be validated, interoperable, and compliant with privacy rules. Leaders should also strengthen education for clinicians and patients on nitrate tolerance, beta blocker titration, calcium channel blocker selection, antiplatelet bleeding risk, drug interactions, lifestyle modification, and when to seek emergency care for unstable symptoms.

Research Methodology for Evidence-Based Angina Pectoris Drugs Analysis

The research methodology for analyzing the angina pectoris drugs landscape should integrate verified clinical, regulatory, epidemiological, and health system evidence. Core sources include peer-reviewed cardiology literature, national and international clinical guidelines, public health databases, medicine regulatory documents, pharmacovigilance communications, essential medicine lists, reimbursement policies, and hospital care pathway publications. Secondary research should be complemented by expert validation from cardiologists, pharmacists, clinical researchers, payers, and health system specialists to assess prescribing behavior, access barriers, treatment adherence, and regional practice variation. The analysis should classify therapies by mechanism of action, clinical indication, route of administration, care setting, and role in symptom relief or secondary prevention. Evidence triangulation is essential to compare findings across scientific publications, public databases, and policy documents while excluding unsupported claims. Quality control should include source recency checks, consistency review, terminology standardization, and validation against accepted cardiovascular disease definitions. The methodology must avoid speculative market sizing or forecasting and instead focus on data-backed trends, regulatory context, therapeutic evolution, patient access, and clinical value.

Conclusion on the Future of Angina Pectoris Drug Innovation and Access

Angina pectoris drugs continue to play a vital role in reducing ischemic symptoms, preventing cardiovascular complications, and supporting long-term coronary artery disease management. The landscape is increasingly shaped by precision in diagnosis, guideline-directed therapy, secondary prevention, medication safety, and patient adherence. Regional differences in healthcare infrastructure, affordability, reimbursement, and specialist access create varied opportunities and challenges, while AI, digital health, real-world evidence, and pharmacovigilance are improving how therapies are developed, selected, and monitored. Industry participants that focus on clinically validated value, equitable access, resilient supply, patient-centered adherence, and integrated cardiovascular care will be best positioned to support improved outcomes in angina management. Sustained progress will depend on coordinated action across clinicians, policymakers, payers, manufacturers, pharmacies, and patient communities to ensure that effective antianginal and cardioprotective therapies reach the right patients at the right time.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Angina Pectoris Drugs Market, by Dosage Form

• 7.1. Introduction
• 7.2. Capsule
• 7.3. Injection
• 7.4. Patch
• 7.5. Tablet

8. Angina Pectoris Drugs Market, by Drug Class

• 8.1. Introduction
• 8.2. Ace Inhibitors
  • 8.2.1. Enalapril
  • 8.2.2. Lisinopril
• 8.3. Antiplatelet Agents
  • 8.3.1. Aspirin
  • 8.3.2. P2Y12 Inhibitors
• 8.4. Beta Blockers
  • 8.4.1. Nonselective
  • 8.4.2. Selective
• 8.5. Calcium Channel Blockers
  • 8.5.1. Dihydropyridines
  • 8.5.2. Nondihydropyridines
• 8.6. Nitrates
  • 8.6.1. Long Acting
  • 8.6.2. Short Acting

9. Angina Pectoris Drugs Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Injectable
  • 9.2.1. Intramuscular
  • 9.2.2. Intravenous
• 9.3. Oral
  • 9.3.1. Controlled Release
  • 9.3.2. Immediate Release
• 9.4. Sublingual
  • 9.4.1. Spray
  • 9.4.2. Tablet
• 9.5. Transdermal
  • 9.5.1. Reservoir
  • 9.5.2. Single Layer

10. Angina Pectoris Drugs Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
  • 10.3.1. Business To Business
  • 10.3.2. Business To Consumer
• 10.4. Retail Pharmacies

11. Angina Pectoris Drugs Market, by End User

• 11.1. Introduction
• 11.2. Clinics
  • 11.2.1. Private Clinics
  • 11.2.2. Public Clinics
• 11.3. Homecare
  • 11.3.1. Caregiver Administered
  • 11.3.2. Self Administered
• 11.4. Hospitals
  • 11.4.1. Private Hospitals
  • 11.4.2. Public Hospitals

12. Angina Pectoris Drugs Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Angina Pectoris Drugs Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Angina Pectoris Drugs Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. AbbVie Inc
• 16.3. Amgen Inc
• 16.4. Astellas Pharma Inc
• 16.5. AstraZeneca PLC
• 16.6. Aurobindo Pharma Limited
• 16.7. Bausch Health Companies Inc
• 16.8. Bayer AG
• 16.9. Boehringer Ingelheim International GmbH
• 16.10. Bristol Myers Squibb Company
• 16.11. Cipla Limited
• 16.12. Daiichi Sankyo Company Limited
• 16.13. Dr Reddys Laboratories Limited
• 16.14. Eli Lilly and Company
• 16.15. F Hoffmann La Roche AG
• 16.16. GlaxoSmithKline PLC
• 16.17. Glenmark Pharmaceuticals Limited
• 16.18. Johnson & Johnson
• 16.19. Les Laboratoires Servier
• 16.20. Lupin Limited
• 16.21. Merck & Co Inc
• 16.22. Novartis AG
• 16.23. Otsuka Pharmaceutical Company Limited
• 16.24. Pfizer Inc
• 16.25. Sanofi S.A.
• 16.26. Sun Pharmaceutical Industries Limited
• 16.27. Takeda Pharmaceutical Company Limited
• 16.28. Teva Pharmaceutical Industries Ltd
• 16.29. Viatris Inc